Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer
The biomarkers were successfully validated across 1000+ patients and 12 centers on four end-points, making it the largest validation study of its kind in bladder cancer.
- The biomarkers were successfully validated across 1000+ patients and 12 centers on four end-points, making it the largest validation study of its kind in bladder cancer.
- View the full release here: https://www.businesswire.com/news/home/20240501832149/en/
The CHAI biomarkers offer independent prognostic capabilities for high-grade recurrence and muscle-invasive progression in bladder cancer. - Validated across more than 1,000 patients and 12 centers, these biomarkers, available through the Vesta test, can enhance first-line treatment decision-making for non-muscle invasive bladder cancer.
- We are able to visualize these biomarkers and gain a better understanding of how tumor morphology correlates to treatment response.”